DRMA (STOCKS)
Dermata Therapeutics, Inc. Common Stock
$1.300000
+0.080000 (+6.56%)
Prev close: $1.220000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Gerald T. Proehl
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $5.29M
- Employees
- 8
- P/E (TTM)
- -0.13
- P/B (TTM)
- 0.52
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
2
Strong Buy
4
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$-1.52 | $-1.57 | +0.0508 | +3.23% |
|
Sep 2025 (Q3)
|
$-1.65 | $-1.62 | -0.0282 | -1.74% |
|
Jun 2025 (Q2)
|
$-1.66 | $-2.96 | +1.2980 | +43.88% |
|
Mar 2025 (Q1)
|
$-4.50 | $-4.59 | +0.0900 | +1.96% |
Financial Statements
| Revenues | $0.00 |
| Operating Expenses | $7.77M |
| Selling, General, and Administrative Expenses | $4.84M |
| Research and Development | $2.93M |
| Operating Income/Loss | -$7.77M |
| Income/Loss From Continuing Operations After Tax | -$7.56M |
| Income/Loss From Continuing Operations Before Tax | -$7.56M |
| Net Income/Loss | -$7.56M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$7.56M |
| Net Income/Loss Available To Common Stockholders, Basic | -$7.56M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$8.16 |
| Diluted Earnings Per Share | -$8.16 |
| Basic Average Shares | 926,192 |
| Diluted Average Shares | 926,192 |
| Assets | $7.86M |
| Current Assets | $7.86M |
| Noncurrent Assets | $0.00 |
| Liabilities | $1.64M |
| Current Liabilities | $1.64M |
| Accounts Payable | $460.81K |
| Wages | $979.45K |
| Other Current Liabilities | $200.18K |
| Noncurrent Liabilities | $0.00 |
| Equity | $6.22M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $6.22M |
| Liabilities And Equity | $7.86M |
| Net Cash Flow From Operating Activities | -$7.76M |
| Net Cash Flow From Operating Activities, Continuing | -$7.76M |
| Net Cash Flow From Investing Activities | -$4.36M |
| Net Cash Flow From Investing Activities, Continuing | -$4.36M |
| Net Cash Flow From Financing Activities | $12.12M |
| Net Cash Flow From Financing Activities, Continuing | $12.12M |
| Net Cash Flow | $0.00 |
| Net Cash Flow, Continuing | $0.00 |
| Comprehensive Income/Loss | -$7.56M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$7.56M |
| Other Comprehensive Income/Loss | $0.00 |